A guide highlighting key information about treatment with DUPIXENT, in terms of the self-injection technique, storage, possible side effects and adverse event reporting. This will support you in managing your patients who have been prescribed DUPIXENT.
The DLQI questionnaire is a patient-reporting tool that consists of 10 questions measuring how their skin condition has affected their life over the last week. A high DLQI score indicates a greater impairment in quality of life. For instructions on how to calculate and interpret a DLQI score, click here.
The POEM questionnaire is a patient-reporting tool that consists of 7 questions designed to measure the severity of atopic dermatitis in your patients. A high POEM score indicates a greater degree of severity. For further information about POEM, click here.
A useful tool explaining the step-by-step process of how to assess and score the severity of your patients’ atopic dermatitis. This will help you give them an accurate assessment and also help with monitoring their atopic dermatitis.
EASI score sheet
An Excel-based score sheet that can be used to calculate and interpret a final EASI score to determine the severity of your patients' atopic dermatitis.
NICE Technology Appraisal Guidance (TA534)3
NICE guidance document published in August 2018 recommending DUPIXENT as a treatment option for adults with moderate-to-severe atopic dermatitis, and explaining in which patients its use may be appropriate.3
Laboratory Monitoring and Ocular Disease
A presentation that outline the monitoring requirements of DUPIXENT and adverse event incidence in ocular disease. The presentation includes information related to the clinical trial programmes on DUPIXENT with particular attention to incidences of conjunctivitis.